How Long Does Wellbutrin Stay in Your System? Why the Five-Day Guess Misses

After chronic dosing, Wellbutrin’s parent drug, bupropion, has a mean elimination half-life of 21 ± 9 hours, so five mean half-lives equal about 4½ days after the last dose. Active metabolites keep the pharmacokinetic clock running: hydroxybupropion has a 20 ± 5-hour half-life, while threohydrobupropion averages 37 ± 13 hours. Medication effects, discontinuation symptoms, and laboratory detection follow separate timelines. A prescriber should guide missed doses, switching, or stopping.

What does “stay in your system” actually mean?

The phrase hides four different questions. Mixing them produces the confident, unsatisfying answers scattered across search results.

| The clock you mean | What it measures | What it can answer | |---|---|---| | Parent-drug clearance | Decline of bupropion itself | A rough estimate of how much unchanged parent drug remains | | Active-metabolite exposure | Hydroxybupropion, threohydrobupropion, and erythrohydrobupropion in circulation | Why one bupropion half-life does not describe total active exposure | | Clinical course | Benefit, side effects, return of symptoms, or symptoms after stopping | How you feel, which cannot be dated from a blood-level calculation alone | | Laboratory detectability | A named analyte measured by a particular method and cutoff | Whether that test may report a result from that specimen |

I learned to separate those last two ideas while collecting environmental swabs in dairy plants. A positive drain sample located an organism in the drain; it did not establish that the organism was on food. Drug clearance and a test result have the same boundary problem. The specimen, analyte, method, and question all matter.

What does the prescribing information say about parent bupropion?

DailyMed’s prescribing information for immediate-release bupropion hydrochloride tablets reports that parent-drug concentrations usually peak within 2 hours. After the initial decline, the terminal phase has a mean half-life of 14 hours, with a range of 8 to 24 hours. Under chronic dosing, the label reports a mean elimination half-life of 21 ± 9 hours and says steady-state plasma concentrations are reached within 8 days.

Those figures describe different study conditions. The 14-hour figure belongs to the terminal phase after oral immediate-release dosing; the 21-hour mean is the label’s chronic-dosing value. Steady state means repeated dosing has brought drug input and elimination into a recurring balance. It says nothing precise about when a person will feel normal after stopping.

Half-life math is still useful. Starting with the chronic-dosing mean, about 50% of the parent amount remains after 21 hours, 25% after 42 hours, and roughly 3% after five half-lives, or 105 hours. “Cleared” in that estimate means greatly reduced. It is not a switch that flips at hour 105, and the ±9-hour spread warns against treating the mean as a personal stopwatch.

Until around 2022, I would answer clearance questions with five parent-drug half-lives and leave it there. I stopped doing that after placing the metabolite table beside the parent figure. Five half-lives estimated parent bupropion while omitting hydroxybupropion, erythrohydrobupropion, and threohydrobupropion.

Why do active metabolites make the simple answer incomplete?

Bupropion is extensively metabolized, and the DailyMed immediate-release label identifies three active metabolites. CYP2B6 is the principal enzyme involved in forming hydroxybupropion. The other two named active metabolites are formed through a different reduction pathway.

| Compound | Mean elimination half-life | Exposure at steady state compared with bupropion | |---|---:|---:| | Parent bupropion after chronic dosing | 21 ± 9 hours | Reference | | Hydroxybupropion | 20 ± 5 hours | About 17 times the AUC | | Erythrohydrobupropion | 33 ± 10 hours | About 1.5 times the AUC | | Threohydrobupropion | 37 ± 13 hours | About 7 times the AUC |

These relative-exposure figures come from the immediate-release prescribing information. AUC, or area under the concentration-time curve, measures total plasma exposure over time. It is not a direct measure of clinical effect. DailyMed also says the potency and toxicity of the metabolites relative to bupropion have not been fully characterized.

The strongest case for the familiar four-to-five-day answer is that it gives a usable estimate for decline of the parent drug. Granted. It works as shorthand when the question truly is “How much parent bupropion remains?” It fails as the whole answer because hydroxybupropion’s steady-state AUC is about 17 times the parent’s in the cited label, and the 37-hour mean half-life of threohydrobupropion is substantially longer than 21 hours.

That comparison also explains why a single parent half-life cannot predict next-day effects. Concentration, receptor activity, sleep, the treated condition, and metabolite exposure do not move in lockstep.

Does IR, SR, or XL change the timing?

Yes. Immediate-release, sustained-release, and extended-release tablets contain bupropion hydrochloride, yet they release it on different schedules. Their parent-drug peak times make the distinction visible.

| Formulation in DailyMed | Reported time to peak parent bupropion concentration | |---|---:| | Immediate-release bupropion hydrochloride tablet | Usually within 2 hours | | Wellbutrin SR | Usually within 3 hours | | Wellbutrin XL | Median of approximately 5 hours in healthy volunteers after one dose |

Peak time is not the same as how long the medicine “works.” The Wellbutrin XL label reports that 14 days of 300 mg once daily produced equivalent peak concentration and AUC for bupropion and its three metabolites when compared with immediate-release 100 mg three times daily. It reports the same equivalence against sustained-release 150 mg twice daily. Those were specific regimens under study conditions, not permission to exchange tablets or schedules yourself.

This is why “Wellbutrin 150 mg duration” is missing a decisive piece. A bottle may pair ER with a second designation: ER (XL) means the once-daily extended-release form, while ER (SR) or SR identifies sustained release. ER by itself is ambiguous, and an immediate-release label may show bupropion hydrochloride without a release suffix. The tablet should stay whole when its labeling says extended- or sustained-release, because crushing, dividing, or chewing changes the intended release rate.

Which health factors can change bupropion exposure?

Kidney function can change both the parent and metabolite picture. DailyMed describes a study in people with moderate-to-severe renal impairment whose mean glomerular filtration rate was 30.9 ± 10.8 mL/min. After one 150 mg sustained-release dose, exposure to parent bupropion was approximately twofold higher than in people with normal renal function. The label does not turn that group average into an individual dosing rule.

In end-stage renal failure, the same prescribing information reports a different pattern. Parent-drug peak concentration and AUC were comparable between groups, while hydroxybupropion and threohydrobupropion AUC increased 2.3-fold and 2.8-fold, respectively. The part of the drug-metabolite system that changed differed between the renal studies.

Liver impairment can alter the clock as well. In the label’s severe hepatic cirrhosis study, mean parent-drug half-life was 29 hours versus 19 hours in healthy participants, with greater variability in exposure. CYP2B6 inhibitors or inducers may also change bupropion and hydroxybupropion exposure. A pharmacist needs the medication list and the actual kidney or liver history; an online half-life calculator has neither.

Does urinary excretion tell you how long Wellbutrin is detectable?

No universal urine or hair window follows from the prescribing information. DailyMed reports that after a 200 mg dose of carbon-14-labeled bupropion, 87% of the radioactive dose was recovered in urine and 10% in feces. Only 0.5% of the oral dose was excreted as unchanged bupropion. The 87% figure includes drug-related material and metabolites; it is not an 87% chance of a positive test or a detection period.

The Wellbutrin labels report false-positive amphetamine immunoassay screens in people taking bupropion, and such results may occur after discontinuation. The label says confirmatory methods such as gas chromatography/mass spectrometry can distinguish bupropion from amphetamines. The FDA likewise describes home urine screens as qualitative and preliminary, with laboratory confirmation needed after a presumptive positive.

I once treated a positive drain swab as though it established product contamination. It cost a repeat sampling round and a correction to the record. The error was assigning a result to a place the sample never represented. With toxicology, the equivalent mistake is quoting “three days in urine” without naming the analyte, specimen, immunoassay or confirmatory method, cutoff, and purpose of the panel.

I have never run a bupropion toxicology assay, and I cannot personally vouch for any laboratory’s cutoff. I can vouch for the sampling discipline of naming what is measured and how a screen is confirmed. Ask the testing program both questions, then disclose prescribed bupropion through its medication-review process rather than trying to accelerate elimination.

Should clearance timing change a missed dose or stopping decision?

A half-life estimate should not be used to double a missed dose, stop treatment abruptly, or improvise a medication switch. The Wellbutrin XL and SR Medication Guides instruct patients who miss a dose to skip it, wait, and take the next dose at the regular time. They warn that excess dosing raises seizure risk. Follow the instructions attached to your own prescription and call a pharmacist when the label is unclear.

For stopping, MedlinePlus tells patients to talk with their doctor first and notes that the dose may be decreased gradually. A bupropion taper is individualized around the formulation, current dose, treatment duration, reason for stopping, symptoms, other medicines, and the next treatment. The Wellbutrin XL label contains a specific step-down from 300 mg to 150 mg for discontinuing seasonal affective disorder treatment; that passage is not a universal taper for every person or indication.

The useful call to a prescriber starts with the exact bottle wording, dose, last dose time, reason for the change, and any kidney or liver condition. Include new agitation, mood worsening, unusual behavior, or other symptoms rather than translating them into “the drug must still be in me.” Seizure, trouble breathing, collapse, or inability to wake warrants emergency help; in the United States, an overdose also calls for Poison Control at 1-800-222-1222.

Frequently asked questions

How long after stopping Wellbutrin will I feel normal?

There is no fixed bupropion withdrawal timeline. Parent bupropion declines over several days, while active metabolites and the return of the treated condition may follow different clocks. Ask your prescriber about symptoms, dose, formulation, treatment length, and other medicines. Urgent mood or behavior changes need prompt clinical attention.

Does Wellbutrin wear off at the end of the day?

A late-day change in how you feel does not prove that bupropion has left your body. SR and XL tablets release bupropion differently, and active metabolites remain between doses. Record the timing of symptoms and doses, then discuss the pattern with your prescriber instead of changing the schedule yourself.

What happens if I stop taking bupropion suddenly?

Some people report symptoms or a return of the condition being treated, but a half-life cannot predict either event for one person. MedlinePlus says to speak with your doctor before stopping and notes that the dose may be lowered gradually. Seek prompt help for severe mood changes or suicidal thoughts.

How long does Wellbutrin XL last during a day?

Wellbutrin XL is designed for once-daily release, and its label reports a median parent-drug peak around 5 hours after one dose in healthy volunteers. That does not mean the medicine stops at a set hour. Metabolites persist, and perceived benefit or side effects may follow a different pattern.

How is a taper decided for bupropion?

A prescriber weighs the exact formulation, current dose, treatment duration, reason for stopping, symptoms, other medicines, and any planned switch. One Wellbutrin XL label step-down applies specifically to seasonal affective disorder treatment. It should not be copied as a universal Wellbutrin tapering schedule for other situations.

Which formulation is on my prescription label?

Look for ER (XL) or XL for once-daily extended release and ER (SR) or SR for sustained release next to “bupropion hydrochloride.” ER alone can be ambiguous, while a label without a release suffix may be immediate-release. Confirm with the dispensing pharmacy; “150 mg” alone does not identify the formulation.

Will Wellbutrin show up on a drug test?

It depends on the panel, analyte, specimen, method, and cutoff. Wellbutrin labels report false-positive amphetamine immunoassay screens, including after discontinuation, while confirmatory gas chromatography/mass spectrometry can distinguish bupropion from amphetamines. Tell the testing program about your prescription and ask how it confirms presumptive results.